当前位置:药药网 / 数据中心 / 儿科标签更改电子表格2021
Opdivo
儿科标签批准日期
2019/4/18 0:00:00
特定指示/秒
Treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC)
标签更改摘要
- New recommended dosage regimens for nivolumab for the treatment of patients with MSI-H or dMMR mCRC in adults and pediatric patients.
- Additionally, a modification of the recommended dosage regimen for nivolumab in adult and pediatric patients 12 years and older with MSI-H or dMMR mCRC for OPDIVO 240 mg intravenously over 30 minutes every 2 weeks until disease progression or unacceptable toxicity, to limit this dosage regimen to adult and pediatric patients weighing 40 kg or more.
- Postmarketing study.